68.77
+2.18%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Royalty Pharma
From its filings with the US Securities and Exchange Commission
Royalty Pharma is based in New York, New York and is incorporated in United Kingdom. Its shares trade on Nasdaq under the ticker RPRX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $2.38bn and net income of $770.9m. At that date it held total assets of $19.62bn and shareholders' equity of $9.71bn. By business, Income from financial royalty assets brought in 95.1% of revenue, followed by Other royalty income and revenues at 4.9%.
We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. We have assembled a portfolio of royalties which entitles us to payments based directly on the top-line sales of many of the industry’s leading therapies, which includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Biogen’s Tysabri and Spinraza, Roche’s Evrysdi, Astellas and Pfizer’s Xtandi, Johnson & Johnson’s Tremfya, AbbVie and Johnson & Johnson’s Imbruvica, Servier’s Voranigo, Gilead’s Trodelvy, Amgen’s Imdelltra and Alnylam’s Amvuttra, among others, and 20 development-stage product candidates.
We strive to be the premier capital allocator in life sciences with consistent, compounding growth. Our highly selective investment approach focuses on identifying and tracking important new therapies, which allows us to act efficiently when opportunities arise. Supported by an experienced investment team, a rigorous due diligence process and a focus on high-quality therapies addressing significant unmet patient needs, we pursue royalty opportunities that best meet our investment criteria.
Quoted from its 10-K, filed 11 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 16 Jun 2020
- Employees
- 100
- Website
- royaltypharma.com ↗
- Head office
- 110 EAST 59TH STREET, NEW YORK, NY, 10022
- Incorporated in
- X0
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Pablo LegorretaChairman of the Board, Chief Executive Officer, since 2020$49.5m
- Mr. Christopher HiteVice Chairman, Executive Vice President$1.3m
- Mr. Terrance CoyneChief Financial Officer, Executive Vice President$1.3m
- Mr. George LloydExecutive Vice President - Investments & Chief Legal Officer, since 2022$1.3m
- Dr. Marshall UristExecutive Vice President - Research & Investments$1.3m
- Dr. Ted LoveLead Independent Director$405,186
- Dr. Bonnie BasslerIndependent Director$405,186
- Dr. Vlad CoricIndependent Director
- Dr. Errol De SouzaIndependent Director$405,186
- Ms. Catherine EngelbertIndependent Director$405,186
- Dr. Carole HoIndependent Director
- Mr. David HodgsonIndependent Director$405,186
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 52
- Environment
- 24
- Social
- 82
- Governance
- 50
- Women in the workforce
- 49%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Royalty Pharma PLC is a leading company in the pharmaceutical industry, with a strong track record of successful investments and acquisitions. The company has a diverse portfolio of royalty interests in various therapeutic areas, providing a stable and reliable source of revenue. Royalty Pharma has established strong relationships with top pharmaceutical companies, enabling them to access a wide range of potential investment opportunities. The company's experienced management team has deep industry knowledge and expertise, ensuring effective decision-making and strategic planning.
Weaknesses
- Royalty Pharma's business model is heavily dependent on the success of the pharmaceutical products it invests in. The company faces the risk of failing to identify profitable investment opportunities or realizing lower-than-expected returns on its investments. Royalty Pharma also operates in a highly regulated industry, which may create challenges in terms of compliance and changes in government policies. The company's revenue streams are subject to fluctuations based on the performance and sales of the underlying pharmaceutical products.
Opportunities
- The pharmaceutical industry continues to evolve, presenting new opportunities for Royalty Pharma to invest in innovative therapies and treatments. Increased global healthcare spending and advancements in medical technology create a favorable environment for growth in the sector. Royalty Pharma can explore partnerships or collaborations with research institutions and biotech companies to access early-stage investment opportunities. Expansion into emerging markets or therapeutic areas can provide additional avenues for revenue and diversification.
Threats
- Royalty Pharma faces intense competition from other investment firms and pharmaceutical companies seeking royalty interests. Rapid changes in the healthcare landscape and regulatory environment can impact the profitability and viability of Royalty Pharma's investments. There is inherent uncertainty and risks associated with the success or failure of clinical trials and regulatory approvals for the pharmaceutical products in which the company holds interests. Economic downturns or market volatility can affect the availability of capital for Royalty Pharma's investment activities.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.